Skip To Main Content
Rebecca Robbins on Muck Rack

Rebecca Robbins

Verified
As seen in: The New York Times, MSN, MSN Australia, MSN India, The New York Times en Español, UOL, Business Insider, Color Research & Application, HuffPost, The Washington Post, TIME and
@nytimes reporter covering medicines rebecca.robbins@nytimes.com 714-478-4224 for calls, texts, Signal or WhatsApp
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Rebecca

Contact Rebecca, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Rebecca Robbins’s Biography

Read Full Bio →

Rebecca Robbins is a reporter covering money in life sciences, a beat that includes business and financial news. She previously reported as an intern for The Washington Post, The Hartford Courant, and The Santa Barbara Independent. Rebecca earned a history degree at Harvard University, where she spent a year as managing editor of The Harvard Crimson.

Articles

A $480,000-a-Year Pill Reflects a New Normal for Cancer Drugs

|
By Rebecca Robbins Verified
| The New York Times Verified
A $480,000-a-Year Pill Reflects a New Normal for Cancer Drugs Rasonque, the new pancreatic cancer treatment from Revolution Medicines, illustrates the huge inflation in cancer drug prices over the past two decades. Daraxonrasib, a newly approved treatment for pancreatic cancer made by Revolution Medicines.Credit...Kim Raff for The New York Times Aug.
Open in Who Shared Issue with article?

El nuevo fármaco contra el cáncer aprobado por la FDA podría ser el primero de muchos

|
By Rebecca Robbins Verified, Carolyn Johnson Verified
| The New York Times en Español Verified
You have a preview view of this article while we are checking your access. When we have confirmed access, the full article content will load. El nuevo fármaco contra el cáncer aprobado por la FDA podría ser el primero de muchos Los investigadores esperan que sea el comienzo de un nuevo capítulo en el tratamiento para una variedad de tipos de cáncer. Una micrografía electrónica de barrido coloreada de células de cáncer de páncreas.
Open in Who Shared Issue with article?

The Race to Develop More Medicines Like the New Pancreatic Cancer Drug

|
By Rebecca Robbins Verified, Carolyn Johnson Verified
| The New York Times Verified
You have a preview view of this article while we are checking your access. When we have confirmed access, the full article content will load. The Race to Develop More Medicines Like the New Pancreatic Cancer Drug Companies are testing dozens of similar drugs in cancers of the pancreas, lung, colon and more. A colored scanning electron micrograph of pancreatic cancer cells.
Open in Who Shared Issue with article?
See all 944 licensed articles (1,870 Total)